2010-04-20-世界卫生组织-ACSoMP_Terms_of_Reference_2页_15kb

The WHO Advisory Committee on Safety of Medicinal Products provides advice to the Director-General and Member States on pharmacovigilance policy, safety, and effectiveness of medicinal products, including blood products, biologicals, herbal medicines, and vaccines. Its key functions involve addressing issues that impact national or international programs, meeting unmet needs, providing policy advice, and promoting advances in pharmacovigilance and training.

The committee consists of 12 members selected for diverse geographical and professional backgrounds, serving renewable terms with rotation to ensure fresh input. It can invite expert observers for specific issues.

Operation includes annual meetings with optional teleconferences or videoconferences, and electronic communication between sessions. The committee elects a Chair and Rapporteur, operates transparently, and prepares reports with potential publication.

The regulations for expert advisory panels apply, except as specified.